Kenichi Inoue
YOU?
Author Swipe
View article: Cultural Adaptation and Preliminary Validation of Adherence Questionnaires for Japanese Patients with Breast Cancer: A Pilot Study
Cultural Adaptation and Preliminary Validation of Adherence Questionnaires for Japanese Patients with Breast Cancer: A Pilot Study Open
This pilot study demonstrated the significance of culturally adapting the BMQ and MARS. Revising or removing culturally incongruent items improved their relevance and reliability for Japanese patients with breast cancer.
View article: Author response: Longitudinal assessment of DREADD expression and efficacy in the monkey brain
Author response: Longitudinal assessment of DREADD expression and efficacy in the monkey brain Open
View article: Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer Open
The addition of a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor to endocrine therapy augments biological response in breast cancer. This phase III randomized, double-blind study evaluated the efficacy of adding palbociclib to neoadjuvant …
View article: Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis
Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis Open
View article: Retrograde Optogenetics Reveals Functional Convergence within a Corticotectal Pathway of Non-Human Primates
Retrograde Optogenetics Reveals Functional Convergence within a Corticotectal Pathway of Non-Human Primates Open
Summary Understanding how the cerebral cortex communicates with subcortical areas to drive behavior remains a central question in system neuroscience. One key unresolved issue is whether prefrontal cortical outputs to motor-related subcort…
View article: Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2
Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2 Open
PURPOSE The MONARCH 2 study demonstrated statistically significant benefit in final progression-free survival (PFS) and interim overall survival (OS) with abemaciclib plus fulvestrant for cyclin-dependent kinase 4/6 inhibitor–naïve hormone…
View article: Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2‐Year Post‐Marketing Surveillance
Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2‐Year Post‐Marketing Surveillance Open
Aim Invasive lobular carcinoma (ILC) is the second most common breast cancer type after invasive ductal carcinoma (IDC). Eribulin mesylate (eribulin) is a non‐taxane microtubule dynamics inhibitor approved for advanced or metastatic breast…
View article: Longitudinal assessment of DREADD expression and efficacy in the monkey brain
Longitudinal assessment of DREADD expression and efficacy in the monkey brain Open
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) offer a powerful means for reversible control of neuronal activity through systemic administration of inert actuators. Because chemogenetic control relies on DREADD expre…
View article: Author response: Longitudinal assessment of DREADD expression and efficacy in the monkey brain
Author response: Longitudinal assessment of DREADD expression and efficacy in the monkey brain Open
View article: Longitudinal assessment of DREADD expression and efficacy in the monkey brain
Longitudinal assessment of DREADD expression and efficacy in the monkey brain Open
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) offer a powerful means for reversible control of neuronal activity through systemic administration of inert actuators. Because chemogenetic control relies on DREADD expre…
View article: AI for Imaging Diagnosis in Breast Cancer Screening
AI for Imaging Diagnosis in Breast Cancer Screening Open
View article: Retrograde Optogenetics Reveals Functional Convergence within a Corticotectal Pathway of Non-Human Primates
Retrograde Optogenetics Reveals Functional Convergence within a Corticotectal Pathway of Non-Human Primates Open
View article: Longitudinal assessment of DREADD expression and efficacy in the monkey brain
Longitudinal assessment of DREADD expression and efficacy in the monkey brain Open
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) offer a powerful means for reversible control of neuronal activity through systemic administration of inert actuators. Because chemogenetic control relies on DREADD expre…
View article: Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) Open
View article: Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC Open
In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus …
View article: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) Open
View article: Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks) Open
Purpose The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) as compared with the standard TCbHP regim…
View article: Embolic stroke due to ascending aortic thrombus in a patient with treatment-resistant ulcerative colitis
Embolic stroke due to ascending aortic thrombus in a patient with treatment-resistant ulcerative colitis Open
The patient was a 49-year-old man presenting with recurrent melena due to progressive ulcerative colitis. One day, he developed left lower facial weakness and dysarthria, and the next day, he was transferred to our hospital because of musc…
View article: Catalytic Oxidation Process and Thermal Characteristics of Toluene and Butyl Acetate Vapor in an Oven
Catalytic Oxidation Process and Thermal Characteristics of Toluene and Butyl Acetate Vapor in an Oven Open
Toluene vapor and butyl acetate vapor were oxidized at 523 K in an oven using the Pt/Co3O4-CeO2, Pt/Al2O3, and Co3O4-CeO2 catalysts and a comparison of activity and thermal characteristic among three different catalysts was conducted. The …
View article: Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice
Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice Open
Aging presents fundamental health concerns worldwide; however, mechanisms underlying how aging is regulated are not fully understood. Here, we show that cartilage regulates aging by controlling phosphate metabolism via ectonucleotide pyrop…
View article: Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole Open
Background An open-label, single-arm, Japanese phase 2 study (J-Ph2) investigated the efficacy and safety of first-line (1L) palbociclib (PAL) + letrozole (LET) in postmenopausal Japanese women with ER+/HER2− advanced breast cancer (ABC). …
View article: Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) Open
View article: Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial Open
PURPOSE Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conj…
View article: 125MO Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
125MO Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks) Open
The randomized phase II Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) vs the standard TCbHP regimen. Pathological comple…
View article: Table S1 from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Table S1 from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer Open
Treatment Discontinuation, Drug Exposure, and Dose Adjustment
View article: Data from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Data from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer Open
Purpose:In MONARCH 2, abemaciclib plus fulvestrant significantly prolonged progression-free survival (PFS) and overall survival (OS) versus placebo plus fulvestrant in patients with hormone receptor positive (HR+), HER2−
View article: Table S1 from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Table S1 from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer Open
Treatment Discontinuation, Drug Exposure, and Dose Adjustment
View article: Data from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Data from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer Open
Purpose:In MONARCH 2, abemaciclib plus fulvestrant significantly prolonged progression-free survival (PFS) and overall survival (OS) versus placebo plus fulvestrant in patients with hormone receptor positive (HR+), HER2−
View article: Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355 Open
Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative bre…
View article: Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study Open